Influence of fluoxetine on olanzapine pharmacokinetics

AAPS Journal

Volumn 4, Issue 2, 2002, Pages

  Gossen, Denis ^a   De Suray, Jean Marie ^a   Vandenhende, Francois ^a   Onkelinx, Claude ^a   Gangji, Diamon ^b  

^a Eli Lilly Benelux   (Belgium)

^b ERASME HOSPITAL   (Belgium)

Author keywords

CYP2D6; Drug interaction; Fluoxetine; Olanzapine; Pharmacokinetics

Indexed keywords

EID: 52449095078     PISSN: 15507416     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Robertson MM, Trimble MR. Major tranquillisers used as antidepressants: a review. J Affect Disord. 1982;4:173-193.
2. Amsterdam JD, Hornig-Rohan M. Treatment algorithms in treatment-resistant depression. Psychiatr Clin North Am. 1996;19:371-386.
3. Fulton B, Goa KL. Olanzapine: a review of its pharmacological properties and therapeutic efficacy in the management of schizophrenia and related psychoses. Drugs. 1997;53:281-298.
4. Callaghan JT, Bergstrom RF, Ptak LR, Beasley CM. Olanzapine: pharmacokinetic and pharmacodynamic profile. Clin Pharmacokinet. 1999;37(3):177-193.
5. Stevens JC, Wrighton SA. Interaction of the enantiomers of fluoxetine and norfluoxetine with human liver cytochrome P450. J Pharmacol ExpTher. 1993;266:964-971.
6. Crewe HK, Lennard MS, Tucker GT, Woods FR, Haddock RE. The effect of selective serotonin re-uptake inhibitors on cytochrome P450D6 (CYP2D6) activity in human liver microsomes. Br J Clin Phamacol. 1992;34:262-265.
7. Bergstrom RF, Peyton AL, Lemberger L. Quantification and mechanism of the fluoxetine and tricyclic antidepressant interaction. Clin Pharmacol Ther. 1992;51:239-248.
8. Catlow JT, Barton RD, Clemens M, Gillepsie TA, Goodwin M, Swanson SP. Analysis of olanzapine in human plasma utilizing reversed-phas e high-performance liquid chromatography with electrochemical detection. J Chromat Biomed Appl. 1995;668:85-90.
9. Nash JF, Bopp RJ, Carmichael RH, Farid KZ, Lemberger L. Determination of fluoxetine and norfluoxetine in plasma with electroncapture detection. Clin Chem. 1982;28:2100-2102.
10. Bergstrom RF, Goldberg MJ, Cerimele BJ, Hatcher BL. Assessment of the potential for a pharmacokinetic interaction between fluoxetine and terfenadine. Clin Pharmacol Ther. 1997;62:643-651.
11. Ring BJ, Binkley SN, Roskos J, Wrighton SA. Effect of fluoxetine, norfluoxetine, sertraline and desmethyl sertraline on human CYP3A catalyzed 1'-hydroxy midazolam formation. J Pharmacol Exp Ther. 1995;275:1131-1135.
12. Ring BJ, Catlow J, Lindsat TL, et al. Identification of the human cytochromes P450 responsible for the in vitro formation of the major oxidative metabolites of the antipsychotic agent olanzapine. J Pharmacol Exp Ther. 1996;276:658-666.
13. Lucas RA, Gilfillan DJ, Bergstrom RF. A pharmacokinetic interaction between carbamazepine and olanzapine: observation and possible mechanism. Eur J Clin Pharmacol. 1998;8:639-643.
14. Nemeroff CB, DeVane CL, Pollock BG. Newer antidepressants and the cytochrome P450 system. Am J Psychiatry. 1996;153:311-320.
15. Brosen K. Differences in interactions of SSRIs. Int Clin Psychopharmacol. 1998;13(suppl 5):45-47.